Bristol-Myers Squibb Co (LIM:BMY) Total Liabilities : $76,215 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Bristol-Myers Squibb Co Total Liabilities?

Bristol-Myers Squibb Co's Total Liabilities for the quarter that ended in Dec. 2024 was $76,215 Mil.

Bristol-Myers Squibb Co's quarterly Total Liabilities declined from Jun. 2024 ($77,577.00 Mil) to Sep. 2024 ($76,470.00 Mil) and declined from Sep. 2024 ($76,470.00 Mil) to Dec. 2024 ($76,215.00 Mil).

Bristol-Myers Squibb Co's annual Total Liabilities declined from Dec. 2022 ($65,702.00 Mil) to Dec. 2023 ($65,674.00 Mil) but then increased from Dec. 2023 ($65,674.00 Mil) to Dec. 2024 ($76,215.00 Mil).

Bristol-Myers Squibb Co Total Liabilities Historical Data

The historical data trend for Bristol-Myers Squibb Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bristol-Myers Squibb Co Total Liabilities Chart

Bristol-Myers Squibb Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

80,599.00

73,308.00

65,702.00

65,674.00

76,215.00

Bristol-Myers Squibb Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															65,674.00	82,483.00	77,577.00	76,470.00	76,215.00

Bristol-Myers Squibb Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Bristol-Myers Squibb Co's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	23774	+	(48973	+	522
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	1055	+	400	+	1491)
	=	76,215

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	92603	-	16388
	=	76,215

Bristol-Myers Squibb Co's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	23774	+	(48973	+	522
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	1055	+	400	+	1491)
	=	76,215

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	92603	-	16388
	=	76,215

Bristol-Myers Squibb Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Bristol-Myers Squibb Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bristol-Myers Squibb Co (LIM:BMY) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

BMYMP.PFD:USA BMY:USA BMY:Mexico 1BMY:Italy BRMd:UK 0R1F:UK BRM:Germany BRM:Germany BRM:Germany BRM:Germany BMYB34:Brazil BMYS:Austria BMY:Argentina

Address

Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543

Website

https://www.bms.com

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.